PDCI Market Access has completed its benchmarking survey on the pan-Canadian Pharmaceutical Alliance (PCPA). We received responses from manufacturers of 7 products that have successfully navigated this important reimbursement process. The purpose of the survey was to gain a better understanding of the PCPA experience from the company perspective.
The survey results suggest that:
- The time between the company receiving a recommendation from an HTA agency and commencing formal PCPA negotiations is typically less than one month;
- There is not any one province that is more likely to take the lead in PCPA negotiations;
- The manufacturer’s preferred number of financial options to present in the negotiations is two;
- The budget impact analysis was viewed as the most critical component of the reimbursement submission during the PCPA negotiation; and
- Ontario was the leader in expeditious listing of products after PCPA negotiations are completed and a letter of intent is signed.
PDCI’s survey report also provides insights on the type of financial agreements negotiated with PCPA (e.g. expenditure cap, patient utilization cap, price rebate, etc.), whether the listing criteria recommended by the HTA agency are modified by the PCPA and the number of rounds of negotiations manufacturers typically go through before arriving an agreement.
PDCI is grateful to those companies that took the time to provide their feedback on this important subject. Please contact Courtney Abunassar, PDCI’s Manager of Market Access and Policy Research, if you are interested in receiving a complimentary copy of the PDCI PCPA Benchmarking Survey Report.